##### 



EXHIBIT 99.1
 
 CHAD Therapeutics Reports
Fiscal 2007 Third Quarter and Nine Months Financial Results
 CHATSWORTH, California, CHAD Therapeutics, Inc. (ASE:CTU)
 2
  Third Quarter Results
  2
    (more)




---



##### 



CHAD Therapeutics Reports Fiscal 2007 Third Quarter and Nine Months Financial Results
  Nine Months Results
  About CHAD Therapeutics
 www.CHADtherapeutics.com
 Safe Harbor Statements under the Private Securities Litigation Reform Act of 1995.
 The foregoing statements regarding prospects for future earnings and revenues, future
sales trends and the introduction of products under development are forward-looking statements that
involve certain risks and uncertainties. A number of important factors could cause actual results
to differ materially from those contemplated by such forward-looking statements. These include the
potential loss of one of our major customers upon whom we depend for a material portion of our
business, increased competition and continuing downward pressure on prices for certain of our
products, the potential introduction of new products with perceived competitive advantages over the
Companys products, changes or proposed changes in health care reimbursement which affect homecare
providers, the terms of any distribution agreement which may be negotiated with respect to our
TOTAL O2 system or our sleep products, and CHADs ability to anticipate and respond to
technological and economic changes in the home oxygen market. The projected timing for the
introduction of new products may be delayed as a result of unforeseen difficulties encountered in
the design, manufacture and quality testing for such products. The Company has limited design and
manufacturing resources and it relies to a significant extent upon independent contractors for the
development of products for the sleep disorder market. As a result, the Company may have more
difficulty ensuring adherence to projected timetables for the introduction of such products.
Moreover, the success of the Companys products and products under development will depend on their
efficacy, reliability and the health care communitys perception of the products capabilities and
benefits, the degree of acceptance the products achieve among homecare providers and, with respect
to products under development, obtaining timely regulatory approval. Additional factors that could
cause actual results to differ materially from those contemplated in this press release can be
found in the Companys annual and quarterly reports filed with the Securities and Exchange
Commission under the caption Risk Factors.




---



##### 



CHAD THERAPEUTICS, INC.
 Three Months Ended
    
    
    Nine Months EndedDecember 31,
    
    
    December 31,2006
    
    
    2005
    
    
    2006
    
    
    2005Net sales
    
    $
    4,307,000
    
    
    $
    5,907,000
    
    
    $
    14,766,000
    
    
    $
    17,177,000Cost of sales
    
    
    3,248,000
    
    
    
    3,806,000
    
    
    
    10,276,000
    
    
    
    11,194,000Gross profit
    
    
    1,059,000
    
    
    
    2,101,000
    
    
    
    4,490,000
    
    
    
    5,983,000Costs and expenses:Selling, general and administrative
    
    
    1,421,000
    
    
    
    1,558,000
    
    
    
    4,805,000
    
    
    
    5,101,000Research and development
    
    
    396,000
    
    
    
    435,000
    
    
    
    1,053,000
    
    
    
    1,202,000Total costs and expenses
    
    
    1,817,000
    
    
    
    1,993,000
    
    
    
    5,858,000
    
    
    
    6,303,000Operating income (loss)
    
    
    (758,000
    )
    
    
    108,000
    
    
    
    (1,368,000
    )
    
    
    (320,000
    )Other income, net
    
    
    18,000
    
    
    
    4,000
    
    
    
    57,000
    
    
    
    23,000Earnings (loss) before income taxes
    
    
    (740,000
    )
    
    
    112,000
    
    
    
    (1,311,000
    )
    
    
    (297,000
    )Income tax expense (benefit)
    
    
    (305,000
    )
    
    
    73,000
    
    
    
    (453,000
    )
    
    
    (84,000
    )Net earnings (loss)
    
    $
    (435,000
    )
    
    $
    39,000
    
    
    $
    (858,000
    )
    
    $
    (213,000
    )Earnings (loss) per share:Basic
    
    $
    (0.04
    )
    
    $
    0.00
    
    
    $
    (0.08
    )
    
    $
    (0.02
    )Diluted
    
    $
    (0.04
    )
    
    $
    0.00
    
    
    $
    (0.08
    )
    
    $
    (0.02
    )Weighted shares outstanding:Basic
    
    
    10,169,000
    
    
    
    10,151,000
    
    
    
    10,169,000
    
    
    
    10,142,000Diluted
    
    
    10,169,000
    
    
    
    10,569,000
    
    
    
    10,169,000
    
    
    
    10,142,000




---



##### 



CHAD THEREAPEUTICS, INC.
 December 31,2006
    
    
    2005AssetsCurrent assets:Cash
    
    $
    1,070,000
    
    
    $
    820,000Accounts receivable, net
    
    
    2,239,000
    
    
    
    3,202,000Income taxes refundable
    
    
    300,000
    
    
    
    402,000Inventories, net
    
    
    6,768,000
    
    
    
    7,356,000Prepaid expenses and other assets
    
    
    292,000
    
    
    
    184,000Deferred income taxes
    
    
    640,000
    
    
    
    501,000Total current assets
    
    
    11,309,000
    
    
    
    12,465,000Property, plant and equipment, net
    
    
    751,000
    
    
    
    1,056,000Intangible assets, net
    
    
    1,094,000
    
    
    
    877,000Deferred income taxes
    
    
    796,000
    
    
    
    376,000Other assets
    
    
    46,000
    
    
    
    74,000Total Assets
    
    $
    13,996,000
    
    
    $
    14,848,000Liabilities and Shareholders EquityCurrent liabilities:Accounts payable
    
    $
    1,132,000
    
    
    $
    862,000Accrued expenses
    
    
    1,260,000
    
    
    
    1,142,000Total current liabilities
    
    
    2,392,000
    
    
    
    2,004,000Capital lease obligation, net of current portion
    
    
    
    
    
    
    5,000Total liabilities
    
    
    2,392,000
    
    
    
    2,009,000Shareholders equity:Common shares, .01 par value,
authorized 40,000,000 shares, 10,169,000
and 10,022,000 issued and outstanding
    
    
    13,480,000
    
    
    
    13,397,000Accumulated deficit
    
    
    (1,876,000
    )
    
    
    (558,000
    )Net shareholders equity
    
    
    11,604,000
    
    
    
    12,839,000Total Liabilities and Shareholders Equity
    
    $
    13,996,000
    
    
    $
    14,848,000